Claims for Patent: 9,023,897

Summary for Patent: 9,023,897

Title:	Biodegradable drug delivery compositions
Abstract:	A biodegradable drug delivery compositions comprising a triblock copolymer containing a polyester and a polyethylene glycol and a diblock copolymer containing a polyester and an end-capped polyethylene glycol, as well as a pharmaceutically active principle is disclosed.
Inventor(s):	Gaudriault Georges
Assignee:	MedinCell
Application Number:	US13340265
Patent Claims:	1. A biodegradable drug delivery composition comprising: {'sub': v', 'w', 'x, 'poly(lactic acid)-poly(ethylene glycol),-poly(lactic acid)'}, '(a) a biodegradable triblock copolymer having the formulawherein v and x are the number of repeat units ranging from 24 to 682 and w is the number of repeat units ranging from 4 to 273 and v=x or v≠x; {'sub': y', 'z, 'methoxy poly(ethylene glycol)-poly(lactic acid),'}, '(b) a biodegradable diblock copolymer having the formulawherein y and z are the number of repeat units, with y ranging from 3 to 45 and z ranging from 7 to 327 wherein the ratio of the biodegradable triblock copolymer of (a) and the biodegradable diblock copolymer of (b) is 1:3 to 1:8 or 1:1 to 1:19 or 3:2 to 1:19 in said biodegradable drug composition, which is insoluble in an aqueous environment; and(c) at least one pharmaceutically active principle.2. A biodegradable drug delivery composition comprising: {'sub': v', 'w', 'x, 'poly(lactic acid)-poly(ethylene glycol)-poly(lactic acid)'}, '(a) a biodegradable triblock copolymer present in an amount of 3.0% to 45% (w%/w%) of the total composition having the formulawherein v and x are the number of repeat units ranging from 24 to 682 and w is the number of repeat units ranging, from 4 to 273 v and x being lactyl or lactoyl repeat units and w being ethylene glycol repeat units and v=x or v≠x; (b) a biodegradable diblock copolymer present in an amount of 8.0% to 50% (w%/w%) of the total composition having the formula:{'sub': y', 'z, 'methoxy poly(ethylene glycol)-poly(lactic acid)'}wherein y and z are the number of repeat units y ranging from 3 to 45 and z ranging from 7 to 327, y being the number of ethylene glycol repeat units and z the number of lactyl or lactoyl repeat units wherein the ratio of the biodegradable triblock copolymer of (a) and the biodegradable diblock copolymer of (b) is 1: 3 to 1:8 or 1:1 to 1:19 or 3:2 to 1:19 in said biodegradable drug composition, which is insoluble in an aqueous environment; and (c) at least one pharmaceutically active principle present in an amount of 1% to 20% (w%/w%) of the total composition.3. The biodegradable drug delivery composition according to claim 1 , wherein said composition is an injectable liquid and forms an implant when injected into the body or are small solid particles or rod implants or spatial formulations.4. The biodegradable drug composition according to claim 1 , wherein the ratio of the biodegradable triblock copolymer of (a) and the biodegradable diblock copolymer of (b) is selected from the group of 1:1 claim 1 , 1:2 claim 1 , 1:3 claim 1 , 1:4 and 1:5.5. The biodegradable drug delivery composition according to claim 1 , wherein the size of the polyethylene glycol chain ranges from 200 Da to 12 kDa or 194 Da to 12 kDa and the size of the methoxy polyethylene glycol chain ranges from 100 Da to 2 kDa or 164 Da to 2 kDA.6. The biodegradable drug delivery composition according claim 1 , further comprising a pharmaceutically acceptable vehicle.7. The biodegradable drug delivery composition according to claim 1 , wherein the pharmaceutically active principle is present in an amount of 1% to 20% (w%/w%) of the total composition.8. The biodegradable drug delivery composition according to claim 1 , wherein the copolymers are present in an amount of 20% to 50% (w%/w%) of the total composition.9. The biodegradable drug delivery composition according to claim 1 , wherein the triblock copolymer is present in an amount of 3.0% to 45% (w%/w%) of the total composition.10. The biodegradable drug delivery composition according to claim 1 , wherein the diblock copolymer is present in an amount of 8.0% to 50% (w%/w%) of the total composition.11. The biodegradable drug delivery composition according to claim 1 , wherein the polylactic repeat unit to ethylene oxide molar ratio in the composition is between 0.5 to 3.5 or 0.5 to 22.3 in the triblock copolymer and 2 to 6 or 0.8 to 13 in the diblock copolymer.112. A method for preparing the biodegradable drug delivery composition of Claim claim 1 , said method comprising: {'sub': v', 'w', 'x, 'poly(lactic acid)-poly(ethylene glycol)-poly(lactic acid),'}, '(i) dissolving in an organic solvent (a) a biodegradable copolymer having the formulawherein v and x are the number of repeat units ranging from 24 to 682 and w is the number of repeat units ranging from 4 to 273 and v=x or v≠x; and {'sub': y', 'z, 'methoxy poly(ethylene glycol)-poly(lactic acid)wherein y and z are the number of repeat units with y ranging from 3 to 45 and z ranging from 7 to 327 in a ratio of 1: 3 to 1:8 or 1:1 to 1:19 or 3:2 to 1:19 (a):(b) to form a polymer mixture, which is insoluble in an aqueous environment; and'}, '(b) a biodegradable diblock copolymer having the formula(ii) adding at least one pharmaceutically active principle to said polymer mixture.113. A method for preparing the biodegradable drug delivery composition of Claim claim 1 , said method comprising: {'sub': v', 'w', 'x, 'poly(lactic acid)-poly(ethylene glycol)-poly(lactic acid)'}, '(i) dissolving in an organic solvent (a) a biodegradable triblock copolymer having the formulawherein v and x are the number of repeat units ranging from 24 to 682 and w is the number of repeat units ranging from 4 to 273 and v=x or v≠x; and {'sub': y', 'z, 'methoxy poly(ethylene glycol)-poly(lactic acid)wherein y and z are the number of repeat units, with y ranging from 3 to 45 and z ranging from 7 to 327 in a ratio of 1:3 to 1:8 or 1:1 to 1:19 or 3:2 to 1:19 (a):(b) to form a polymer mixture, which is insoluble in an aqueous environment; and'}, '(b) a biodegradable dibiock copolymer having the formula(ii) adding at least one pharmaceutically active principle to said polymer mixture; and(iii) evaporating said solvent.014. The method according to claim 12 , wherein the organic solvent is selected from the group of benzyl alcohol claim 12 , benzyl benzoate claim 12 , dimethyl isosorbide (DMI) claim 12 , dimethyl sulfoxide (DMS) claim 12 , ethyl acetate claim 12 , ethyl benzoate claim 12 , ethyl lactate claim 12 , glycerol formal claim 12 , methyl ethyl ketone claim 12 , methyl isobutyl ketone claim 12 , N-ethyl-2-pyrrolidone claim 12 , N-methyl-2-pyrrolidinone(NMP) claim 12 , pyrrolidone-2 claim 12 , tetraglycol claim 12 , triacetin claim 12 , tributyrin claim 12 , tripropionin claim 12 , and mixtures thereof.15. The method according to claims 12 , wherein the organic solvent is present in an amount of 40% to 74% (w%/w%) of the total composition.16. The biodegradable drug composition according to claim 1 , further comprising an organic solvent selected from the group of benzyl alcohol claim 1 , benzyl benzoate claim 1 , dimethyl isosorbide (DMI) claim 1 , dimethyl sulfoxide (DMSO) claim 1 , ethyl acetate claim 1 , ethyl benzoate claim 1 , ethyl lactate claim 1 , glycerol formal claim 1 , methyl ethyl ketone claim 1 , methyl isobutyl ketone claim 1 , N-ethyl-2-pyrrolidone claim 1 , N-methyl-2-pyrrolidinone(NMP) claim 1 , pyrrolidone-2 claim 1 , tetraglycol claim 1 , triacetin claim 1 , tributyrin claim 1 , tripropionin and mixtures thereof.17. The biodegradable drug composition according to claim 2 , further comprising an organic solvent selected from the group of benzyl alcohol claim 2 , benzyl benzoate claim 2 , dimethyl isosorbide (DMI) claim 2 , dimethyl sulfoxide (DMSO) claim 2 , ethyl acetate claim 2 , ethyl benzoate claim 2 , ethyl lactate claim 2 , glycerol formal claim 2 , methyl ethyl ketone claim 2 , methyl isobutyl ketone claim 2 , N-ethyl-2-pyrrolidone claim 2 , N-methyl-2-pyrrolidinone(NMP) claim 2 , pyrrolidone-2 claim 2 , triacetin claim 2 , tributyrin claim 2 , tripropionin and mixtures thereof18. The biodegradable drug delivery composition according to claim 17 , wherein said composition is an injectable liquid and forms an implant when injected into the body or are small solid particles or rod implants or spatial formulations.